PI3K

February 14, 2017

New Oral Drug Shows Promise in Halting Growth of B-Cell Lymphoma Tumors

News

By simultaneously inhibiting two proteins that cancer cells need to survive, researchers offer a potentially promising therapeutic approach to treat B-cell lymphomas, according to a new study. CUDC-907, a new oral ... Read more

May 2, 2016May 2, 2016

New PI3K Delta Inhibitor to Treat Blood Cancers Shows Promise in Early Clinical Study

News

MEI Pharma recently presented promising clinical results from a new oral phosphatidylinositol 3 kinase (PI3K) delta inhibitor, ME-401, that may improve the therapeutic window in cancer patients compared to other PI3K ... Read more

December 2, 2015December 2, 2015

Lymphoma Study Traces 2 Key Players’ Opposing Roles in B Cell Development

News

In a new study, scientists discovered that two key players in B cells, PI3 Kinase and FOXO1, have opposing roles in controlling B cell proliferation and differentiation in germinal centers, with implications ... Read more